Page 11 - Servier Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis Share Article Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020. BUDAPEST, Hungary (PRWEB) March 16, 2021 The PREDYSTIC® Infliximab RA Kit is a first-in-class, CE IVD labelled, molecular biomarker diagnostic system, suitable for predicting infliximab responsiveness in rhe...

Critical Path Institute and global partners establish Ataxia Consortium Critical Path Institute (C-Path) today announced the launch of the Critical Path to Therapeutics for the Ataxias (CPTA) Consortium, a public-private partnership focused on optimizing clinical trials for inherited ataxias. CPTA is a collaborative effort between C-Path, Ataxia Global Initiative, the National Ataxia Foundation, Ataxia UK and key partners in the industry and academic research communities, including Biohaven Pharmaceuticals, Ionis Pharmaceuticals, Roche Pharmaceuticals, Servier Group, Triplet Therapeutics, uni...

Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target. Servier, a global and independent pharmaceutical Group, and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005329/en/ As part of the coll...

Valeo Pharma Announces Major Addition to its Senior Management Team News provided by Share this article Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors MONTREAL, Jan. 18, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo" or the " Company"), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo's commercial activities. Mr. Fasa...

Posted January 7th, 2021 for Servier Paris, France, 7 January 2021 – Servier, a global independent pharmaceutical company , today announced the appointment of Pascal Lemaire as Executive Vice President Finance. He succeeds Dominique Brissy, Executive Vice President Finance since 2014, who will retire at the end of January 2021. As Executive Vice President Finance, Pascal Lemaire joins the Executive Committee of the Servier Group and the Foundation Board.   Pascal Lemaire has over 20 years’ experience in corporate finance, particularly on an international level in the consumer ...